Prime Therapeutics’ Post

CX-2051 has amazing potential to bring benefit to EpCAM+ solid tumor patients, notably in CRC where there is significant unmet need. The program is a shining example of how CytomX Therapeutics applies our masked PROBODY platform to ADCs to increase therapeutic index by minimizing on-target, off-tumor toxicity. Particularly beneficial when the target also has broad healthy tissue expression (like EpCAM).

Merck and Moderna are beginning recruitment for a phase III trial for V940 in combination with Keytruda to treat patients with high-risk #melanoma. Together, they hope to see V940 generate an increased immune response based on the specific mutation of the tumor. The trial is an important step in developing a better treatment option for patients with high-risk Stage IIB-IV melanoma and to better understand individualized neoantigen therapy. https://hubs.la/Q01Z74CB0

🔬 On February 17, 2024, the FDA granted accelerated approval to Amtagvi (lifileucel), the world's first TIL therapy targeting solid tumors. This marks a significant breakthrough in personalized T-cell therapy. With promising open-label phase II trial results boasting a 31.5% overall response rate, lifileucel offers hope to patients who have exhausted standard treatments. Despite challenges, ongoing research aims to expand its applications beyond melanoma. Let's celebrate this milestone and support innovative treatments like lifileucel, bringing hope to cancer patients worldwide. Learn more about selected TIL therapies in the clinic 👉🏻 https://lnkd.in/eDtX8tZA #KACTUS #CancerResearch #FDAApproval #TILTherapy #CellTherapy

If you are diagnosed with ER+/HER2- advanced or metastatic breast cancer with ESR1 mutation, read this summary about the new FDA-approved drug called ORSERDU. https://lnkd.in/eP6XYbri

Projected 2024 Drug Approvals by Chris Di Savi. Claudin 18.2: gastric cancer TILs: melanoma Thb: NASH HT2A: schizophrenia Activin-R: PAH HIF-PHIs: CKD Aβ: AD HER3 ADC: NSCLC RAFi: glioma Telomerase: MDS/MF DLL3-CD3: SCLC FIX: Hem B FDi: PNH C5i: PNH KarXT: schizophrenia

Clinical trial update! We are thrilled to report that our VET3-TGI novel oncolytic immunotherapy is ready for Phase 1/1b testing in incurable advanced solid tumors. VET3-TGI specifically targets and preferentially kills tumor cells directly while stimulating anti-cancer immunity by expressing its therapeutic payload consisting of the transgenes for interleukin-12 and a TGFbeta inhibitor. The study will evaluate the safety profile and efficacy of VET3-TGI when administered as a monotherapy and in combination with checkpoint inhibitor therapy. https://bit.ly/3xF6jmu

Lymph nodes (LNs) can serve as the initial site to activate anti-tumor immunity to initiate the cancer immune cycle cascade, thereby achieving effective anti-tumor immunotherapy. Therefore, drug delivery through the lymphatic system has become an attractive strategy for tumor immunotherapy. In view of this, the researchers constructed a nanomedicine with dual responsiveness to pH and enzymes, which can programmatically activate anti-tumor immunity through the lymphatic system. https://lnkd.in/gGbuH7nW 

The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests. https://ow.ly/iH9A50Pcg59 @nciccr_gmb @NCIResearchCtr

Did you know, Wilms’ Tumor 1 (#WT1) is known to be over-expressed in numerous cancers, including solid tumors and hematologic malignancies? Learn about our second drug product candidate designed to activate and expand T cells that target WT1-expressing cancers: https://bit.ly/3P0oVSu

There is an interesting discussion regarding the mechanisms-of-action for sorafenib. Several other tyrosine kinase inhibitors have not been able to demonstrate efficacy against hepatocellular carcinoma (most common primary liver cancer). This suggest that overall effect of sorafenib involves mechanisms other than kinase inhibition to achieve its anti-tumor effects. One such mechanism proposed is sorafenib-induced ferroptosis, which is discussed in paper by Wang et al in 2024.